Pharma / Biotech

High Cost Trips Up Oral Chemotherapy Initiation

Denver—Many patients are abandoning or delaying initiation of their oral oncolytic therapies because of the high cost of the medication, according to the results of a survey of pharmacy staff and administrators presented at the 2018 annual meeting of the Hematology/Oncology Pharmacy Association (poster TR165).

Source link

Related posts

journal pharmacology; +792 new citations


Efficacy and Safety of an Albiglutide Liquid Formulation Compared With the Lyophilized Formulation: A 26-Week Randomized, Double-Blind, Repeat-Dose Study in Patients With Type 2 Diabetes Mellitus.


Impact of obesity on the toxicity of a multi-ingredient dietary supplement, OxyELITE Pro™ (New Formula), using the novel NZO/HILtJ obese mouse model: Physiological and mechanistic assessments.


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy